Oral Minoxidil: Restarting After Acute Illness

Is there a standard restart plan after an illness?

No. Neither the label nor the low-dose alopecia studies give a dose to resume at or a schedule for moving back up after an acute illness. The studies of low-dose oral minoxidil for hair loss report adverse-effect rates in people on treatment [2][3].

What the oral tablet label says

The label covers one product: minoxidil tablets, indicated only for hypertension that is symptomatic or involves target organ damage and is not manageable with maximum doses of a diuretic plus two other antihypertensive drugs [1]. The same label states that use of minoxidil tablets, in any formulation, to promote hair growth is not an approved indication [1].

Its boxed warning describes a powerful antihypertensive that can cause pericardial effusion, occasionally progressing to tamponade, and can exacerbate angina. It directs that the drug be given under close supervision, usually with a beta blocker to prevent tachycardia and increased myocardial workload and with a diuretic, often a loop diuretic, to prevent serious fluid accumulation [1]. Salt and water retention is the first listed warning: reversible edema developed in about 10% of non-dialysis patients, and a loop diuretic is almost always needed [1]. Pericardial effusion, occasionally with tamponade, has been observed in about 3% of treated patients not on dialysis, especially those with compromised kidney function [1]. The label also states that minoxidil has not been studied in patients within 1 month of a heart attack [1].

For patients over 12, the label starts at 5 mg once daily and increases to 10, 20 then 40 mg if needed, with a usual effective range of 10 to 40 mg per day and intervals of at least 3 days between adjustments [1]. Hair-loss regimens of 5 mg per day or less sit far below that range and are off-label [1][3].

The label states that minoxidil itself does not produce orthostatic hypotension, and it names guanethidine as the only interacting drug, one that can produce profound orthostatic effects when given with minoxidil [1].

What the low-dose safety data show

A retrospective multicenter study of 1,404 patients (943 women, 461 men, mean age 43) treated for at least 3 months found hypertrichosis in 15.1% (0.5% stopped the drug because of it), lightheadedness in 1.7%, fluid retention in 1.3%, tachycardia in 0.9% and periorbital edema in 0.3%. Systemic effects led to discontinuation in 1.2%, and there was no control group [2].

A 2025 meta-analysis of studies using 5 mg per day or less found no significant change in systolic blood pressure (mean difference -0.13 mm Hg, 95% CI -2.67 to 2.41) or diastolic pressure (-1.25, 95% CI -3.21 to 0.71), a heart rate increase of 2.67 beats per minute (95% CI 0.34 to 5.01), and hypotensive symptoms in 119 patients (5.0%), with no hypotensive episodes recorded. The included studies were uncontrolled [3].

What about hair shedding around a restart?

A 2012 review attributes the increased hair loss that can occur during minoxidil use to synchronization of the hair cycle, and says measurable changes disappear within months of stopping [4]. At antihypertensive doses the label reports hypertrichosis in about 80% of patients, beginning within 3 to 6 weeks, with new growth stopping on discontinuation and 1 to 6 months needed to return to pretreatment appearance; no endocrine abnormality explains it [1].